The other thing people may have missed is the deltas/differences between their submitted Amendment #2 and Amendment #3.
Amendment #3 reduces the terms of the warrant enabling Boustead to purchase GMVD shares for the first 5 years after listing. It was originally up to 7% of shares sold at an exercise price of 125% of the offering price. This has now been amended to 2% of total shares sold at an exercise price of 155% of the public offering price.
So Boustead's warrant is now for fewer shares at an increased premium...I'm still trying to work out what this means...also, the underwriting agreement Poorrundownhill correctly references has not been amended and re-submitted to reflect these new values...https://www.sec.gov/Archives/edgar/data/1760764/000121390020033625/ea129014ex1-1_gmedicalinno.htm
- Forums
- ASX - By Stock
- GMV
- GMVD - NASDAQ IPO
GMVD - NASDAQ IPO, page-398
-
-
- There are more pages in this discussion • 1,534 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online